来到中德（太仓）中小企业合作示范区，"德企密度"令人感叹。沿着103路公交车线路行走，4公里 范围内聚集40多家外资企业。一个数字更令人惊叹：整个示范区已吸引超560家德国企业落户，年工业 产值超670亿元。 近4.3万家外资企业以近1%的户数占比，贡献46.6%的进出口额、19.2%的综合税收和8.4%的城镇就 业；2024年实际使用外资190.5亿美元，4年累计1037.4亿美元，外资规模始终保持全国首位；世界500强 企业中有408家前来投资……这里，就是江苏。 在全球产业链与供应链格局重塑、国内产业转型升级的双重挑战与机遇之下，江苏作为我国对外开 放的前沿阵地，如何在风浪中稳住外资基本盘？ "活力中国调研行"采访团深入江苏各地，从车间流水线到研发实验室，从外资项目建设现场到产业 链协同一线，透过一个个跃动的数据、鲜活的案例，寻找外资愿意持续"加码"江苏的原因，共探这个外 资大省的"进阶之路"。 规模与质效双领先：从"增资扩产"到"链式发展" "1993年，'克恩—里伯斯'作为首家德企来到太仓时，周边不少地方还是农田、荒地。如今，企业 已从最初几十人的团队，发展到建设17座工厂，形成涵盖研发、制造、人才 ...

Group 1 - Jiangsu Youao Intelligent Technology Co., Ltd. increased R&D efforts to meet specific demands in Germany, France, and Southeast Asia, achieving an export sales revenue of 823 million yuan, a year-on-year increase of 10.38%, despite a 20% decline in the U.S. market [1][3] - In 2024, Jiangsu's foreign trade import and export is expected to reach 5.62 trillion yuan, marking a historical high and maintaining the second position nationally for 22 consecutive years [1][3] - Jiangsu attracted 19.05 billion USD in actual foreign investment in 2024, ranking first in the country for seven consecutive years [1] Group 2 - Nanjing Konne Electric Co., Ltd. successfully delivered high-speed train doors in collaboration with Nanjing Engineering Institute, showcasing its innovation capabilities [2][3] - The company emphasizes the importance of R&D investment, with approximately 3.5% of revenue allocated to R&D, enabling rapid product development and maintaining industry leadership [3] Group 3 - Bosch Siemens Home Appliances (Jiangsu) Co., Ltd. upgraded its R&D center in Nanjing to a global R&D center, highlighting China's market potential and talent resources [4][5][6] - Hawe China has the highest manufacturing efficiency and lowest costs among its global subsidiaries, benefiting from a robust supply chain in the Yangtze River Delta region [6][7] Group 4 - Jiangsu has implemented strategies to optimize the business environment and support foreign enterprises, including tailored services to help foreign companies navigate local supply chains [9][10] - The region has organized various events to facilitate supply-demand matching and promote foreign trade enterprises' participation in international exhibitions [10]

Summary of the Conference Call for Meihua Medical Industry and Company Overview - **Company**: Meihua Medical - **Industry**: Medical Devices, specifically focusing on home respiratory devices, cochlear implants, blood glucose management products, and robotics Key Points and Arguments 1. **Home Respiratory Device Business**: - Short-term decline due to factory relocation, expected recovery in Q4 with increased customer inventory replenishment needs [2][3][4] - Current six-month orders and forecasts aim to meet annual targets [5] 2. **Cochlear Implant Business**: - Recovery from previous disruptions caused by rare earth material controls, with normal shipments expected to resume in the second half of the year [2][6] - Anticipated positive impact on overall performance [2] 3. **Blood Glucose Management Products**: - Stable production of insulin pens and new orders for weight loss pens expected to start deliveries in Q1 2026 [7] - Continuous growth in Continuous Glucose Monitoring (CGM) products, with bulk deliveries starting in Q2 and further expansion planned for 2026 [7] 4. **Tariff Impact Mitigation**: - Partial production capacity has been relocated to Malaysia to address tariff impacts and meet domestic and international market demands [8] - Collaboration with overseas clients, including Johnson & Johnson, to enter the domestic market [8] 5. **Shareholder Concerns**: - No significant share reduction risk as the controlling shareholder and employee stock platform have no plans to sell shares until the end of the year [9] 6. **Profitability Metrics**: - Decline in net profit margin at the Huizhou subsidiary reflects an overall decrease in gross margin, primarily due to short-term factors affecting core businesses [10] - Expected recovery in overall performance as these factors dissipate and emerging businesses grow [10] 7. **Gross Margin Decline**: - The decrease in gross margin attributed to increased costs from capacity adjustments and rising operational expenses [11] 8. **Production Capacity and Supply Chain**: - Completion of the relocation of respiratory device component production, with 20%-30% capacity retained domestically and 70%-80% supplied from overseas [12] - New production capacity planning based on customer orders and automation requirements [17] 9. **Brain-Computer Interface (BCI) Development**: - Ongoing research and development in BCI technology based on cochlear implant expertise, with collaborations for invasive electrode development [18][19] - Current projects are in early R&D stages, with no defined commercialization timeline yet [22] 10. **Robotics Business Exploration**: - Focus on lightweight components, micro-motors, and flexible skin sensor technology for robotics applications [27] - Development of proprietary sensor technologies to enhance product offerings [28][29] 11. **Market Positioning**: - Meihua Medical holds approximately 70% of the global cochlear implant market, making it a preferred partner for clients [24] - The company’s experience in long-term implant safety enhances its attractiveness to both domestic and international clients [24] 12. **Future Revenue Projections**: - Shift in revenue structure anticipated, with increased focus on larger market segments such as insulin pens and CGM products [32] - The company aims to balance its revenue sources between traditional and emerging product lines [32] 13. **Cochlear Implant Market Growth**: - Despite a slow overall market growth rate of 5-6%, Meihua Medical expects to achieve a growth rate of around 15% due to stable replacement demand [36] 14. **CGM Business Outlook**: - Positive future outlook for CGM business with plans for factory expansion in Malaysia and stable pricing models that mitigate the impact of terminal price fluctuations [39] Additional Important Information - The company is actively exploring new product developments and collaborations to enhance its market presence and technological capabilities across various medical device sectors [28][30] - The strategic focus on R&D and innovation is expected to drive long-term growth and profitability [31]

Core Insights - The Swiss company Medtronic has established a production base in Changzhou, China, focusing on the growing market for chronic disease management and self-injection devices [1][2] - The company has doubled its initial investment to €100 million, indicating strong confidence in the Chinese market [2] - The production facility is expected to start operations in June 2025, with an annual capacity of 100 million injection pens [2] Company Overview - Medtronic specializes in the development, production, and sales of injection pens and automatic injectors, serving major pharmaceutical companies globally [1] - The company has chosen Changzhou for its strategic advantages, including location, transportation, cost, and business environment [1][2] Market Dynamics - The demand for liquid formulations over traditional tablets is increasing, driven by better absorption rates, particularly for diabetes and obesity treatments [1] - The local industrial ecosystem in Changzhou supports Medtronic's operations, with nearby suppliers enhancing efficiency and reducing costs [3] Investment and Growth - The Changzhou project was approved in April 2023 and construction began in September 2023, with the main factory completed in just 14 months [2] - Medtronic's investment reflects a broader trend of foreign companies entering the Changzhou market, with foreign direct investment reaching $863 million in the first seven months of 2025, a year-on-year increase of 18.9% [5] Infrastructure and Logistics - The proximity to high-speed rail networks facilitates quick transportation to major cities like Shanghai and Nanjing, enhancing operational efficiency [6] - The local government is proactive in supporting foreign enterprises, contributing to a favorable business environment [2][5]

Group 1: Guocera Materials - The company is developing both oxide and sulfide solid electrolyte technologies and has established a joint venture focused on sulfide [1] - The honeycomb ceramic products have shown steady growth, covering domestic automotive brands and entering the supply chains of international leading car manufacturers [1] - The subsidiary Guocera Saichuang has mass-produced and sold ceramic substrates for optical modules, with plans for increased investment after the completion of the second-phase factory [1] - The company is expanding its market share in automotive and server MLCCs, with limited impact from rare earth regulations [1] Group 2: Rabbit Baby - The distribution channels for decorative materials are composed of 38.5% from distributors, 49.6% from furniture factories, 8.1% from home decoration companies, and 3.8% from engineering [2] - The company has seen growth in rural channels, with 847 new stores opened and 600,000 sales of decorative boards in the first half of the year [2] - Gross margins in the decorative materials business have improved due to cost control measures and a 9.9% increase in auxiliary material sales [2] - The custom home business has shown stable growth, with a 46.5% year-on-year increase in sales through home decoration company channels [2] Group 3: Meihua Medical - In the first half of 2025, the company achieved revenue of 733 million yuan and a net profit of 114 million yuan, with adjusted net profit of 129 million yuan [3] - The company has increased R&D investment, with home and consumer electronics components revenue growing by 35.69% and other medical product components by 54.41% [3] - The company is advancing its investment and acquisition efforts while focusing on risk control [3] - The company has begun mass deliveries of injection pens and CGM products, and is exploring the humanoid robot industry [3]

Group 1: 京北方 - 京北方 has made significant progress in AI technology, particularly in banking business scenarios, with multiple innovative cases expected to be implemented by the first half of 2025 [1] - The company plans to deepen its AI layout, focusing on technology research and development, product innovation, and business scenario implementation, leveraging its AI platform to empower financial institutions comprehensively [1] - 京北方 is exploring a performance-based payment model with clients, which has received a high acceptance rate, and the demand for AI technology continues to rise, leading to a sustained increase in AI-related business orders [1] - The company is collaborating with Guofu Quantum to assess existing system capabilities and plan future construction, aiming to establish a cross-industry and cross-regional digital asset ecosystem [1] Group 2: 美好医疗 - 美好医疗 achieved a revenue of 733 million yuan and a net profit of 114 million yuan in the first half of 2025, with a net profit of 129 million yuan after excluding share-based payment impacts [2] - The company increased its R&D investment, with revenue from home and consumer electronic components growing by 35.69% year-on-year, and other medical product components increasing by 54.41% [2] - The Malaysian Phase III project is expected to be completed by the end of the year, with current production capacity meeting customer demand and a healthy utilization rate [2] - 美好医疗 has formed an investment and acquisition team to advance M&A efforts while emphasizing risk control [2] - The company has begun bulk deliveries of injection pens and CGM products since the second quarter, and has a long-standing partnership with Johnson & Johnson, while also exploring the humanoid robot industry [2]

Core Insights - The "Su Super" league is enhancing connections between cities in Jiangsu, expanding its influence internationally and creating opportunities for economic and social development [1] Group 1: Investment Opportunities - The "Su Super" league has attracted foreign enterprises to Jiangsu, with over 100 executives from multinational companies attending a match in Yancheng to discuss investment and development [2] - Yancheng's collaboration with multinational companies has diversified, expanding from South Korea to include firms from Europe, America, Southeast Asia, and Japan [2] - The city of Changzhou has hosted multiple events for foreign enterprises, fostering emotional and cultural connections among expatriates and local businesses [3][4] Group 2: Economic Impact - The "Su Super" league has stimulated local consumption, with significant increases in visitor numbers and sales during match weekends, indicating a boost in the local economy [9][10] - In Yancheng, key monitored businesses reported a 20.1% increase in sales and a 22.1% rise in foot traffic during the league matches [10] - Changzhou's foreign investment quality is improving, with actual foreign capital usage reaching $739 million in the first half of the year, a year-on-year increase of 8.3% [7] Group 3: Cross-Border Collaboration - The league has facilitated cross-border cooperation, with companies like SMC and Medtronic establishing collaborative agreements following interactions during matches [6][7] - The presence of foreign representatives from regions like North Brabant in the Netherlands has led to discussions on agricultural and renewable energy collaborations with Yancheng [8] - The "Su Super" league is seen as a platform for enhancing international cooperation, with plans for future events targeting global CEOs to further drive investment [11]

Group 1 - The "Su Super" league is enhancing connections between cities in Jiangsu, expanding its influence internationally and creating more opportunities for economic and social development [1] - The event attracted over 100 executives from multinational companies and associations to Salt City, showcasing the city's potential for investment and collaboration [1][2] - Salt City has shifted its collaboration with multinational companies from sporadic to diversified, attracting attention from global firms [1][2] Group 2 - The "Su Super" league has facilitated communication and cultural connections among foreign professionals, enhancing their integration into local communities [2][3] - The league has become a popular topic for social interactions among expatriates, fostering friendships and potential business collaborations [3] - The event has been recognized as an innovative practice for promoting international cooperation through sports [3] Group 3 - The league has led to successful collaborations between companies, exemplified by a partnership between medical device manufacturer Medtronic and SMC, which resulted in expedited service due to their proximity [5][6] - Companies like Medtronic and SMC are increasing their investments in Changzhou, reflecting the city's growing appeal for foreign investment [6] - In the first half of the year, Changzhou attracted $739 million in foreign investment, marking an 8.3% year-on-year increase [6] Group 4 - The "Su Super" league has stimulated local consumption and investment, with significant increases in visitor numbers and sales during the event [9] - Salt City reported a 20.1% increase in sales and a 22.1% rise in visitor numbers during the league's eighth round [9] - Companies are leveraging the league's popularity to enhance their brand presence and sales, as seen with Yueda Kia's sponsorship [9] Group 5 - Changzhou is planning to host a "Global CEO Watch 'Su Super'" event to attract potential investors and enhance its investment appeal [10] - The league serves as a platform for cultural exchange and economic integration, reflecting the city's commitment to fostering long-term business relationships [10] - The ongoing success of the league is seen as a catalyst for sustained economic development in Jiangsu [10]